Glioma susceptibility 1

Common Name(s)

Glioma susceptibility 1

Gliomas are central nervous system neoplasms derived from glial cells and comprise astrocytomas, glioblastoma multiforme, oligodendrogliomas, ependymomas, and subependymomas. Glial cells can show various degrees of differentiation even within the same tumor (summary by {61:Kyritsis et al., 2010}). Ependymomas are rare glial tumors of the brain and spinal cord ({114:Yokota et al., 2003}). Subependymomas are unusual tumors believed to arise from the bipotential subependymal cell, which normally differentiates into either ependymal cells or astrocytes. They were characterized as a distinct entity by {92:Scheinker (1945)}. They tend to be slow-growing, noninvasive, and located in the ventricular system, septum pellucidum, cerebral aqueduct, or proximal spinal cord (summary by {89:Ryken et al., 1994}). Gliomas are known to occur in association with several other well-defined hereditary tumor syndromes such as mismatch repair cancer syndrome ({276300}), melanoma-astrocytoma syndrome ({155755}), neurofibromatosis-1 (NF1; {162200}) and NF2 ({101000}), and tuberous sclerosis (TSC1; {191100}). Familial clustering of gliomas may occur in the absence of these tumor syndromes, however. Genetic Heterogeneity of Susceptibility to Glioma Other glioma susceptibilities include GLM2 ({613028}), caused by variation in the PTEN gene ({601728}) on chromosome 10q23; GLM3 ({613029}), caused by variation in the BRCA2 gene ({600185}) on chromosome 13q12; GLM4 ({607248}), mapped to chromosome 15q23-q26.3; GLM5 ({613030}), mapped to chromosome 9p21; GLM6 ({613031}), mapped to chromosome 20q13; GLM7 ({613032}), mapped to chromosome 8q24; GLM8 ({613033}), mapped to chromosome 5p15; and GLM9, caused by variation in the POT1 gene ({606478}) on chromosome 7q31. Somatic mutation, disruption, or copy number variation of the following genes or loci may also contribute to the formation of glioma: ERBB (EGFR; {131550}), ERBB2 ({164870}), LGI1 ({604619}), GAS41 ({602116}), GLI ({165220}), DMBT1 ({601969}), IDH1 ({147700}), IDH2 ({147650}), BRAF ({164757}), PARK2 ({602544}), TP53 ({191170}), RB1 ({614041}), PIK3CA ({171834}), 10p15, 19q, and 17p13.3.
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Glioma susceptibility 1" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
Top

How do you compare to others with this condition?

Privately answer questions about your health. Let resources, you select, come to you.

Anonymously share and see how your answers compare with others with this condition while privately providing key pieces of information to medical researchers, disease advocacy groups, and others ONLY YOU select to help speed up cures and better alternatives.

 
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Glioma susceptibility 1" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
 
 
Top

Scientific Literature

Articles from the PubMed Database

Research articles describe the outcome of a single study. They are the published results of original research.
The terms "Glioma susceptibility 1" returned 2 free, full-text research articles on human participants. First 3 results:

AEG-1/MTDH-activated autophagy enhances human malignant glioma susceptibility to TGF-β1-triggered epithelial-mesenchymal transition.
 

Author(s): Meijuan Zou, Wei Zhu, Li Wang, Lei Shi, Rui Gao, Yingwei Ou, Xuguan Chen, Zhongchang Wang, Aiqin Jiang, Kunmei Liu, Ming Xiao, Ping Ni, Dandan Wu, Wenping He, Geng Sun, Ping Li, Sulan Zhai, Xuerong Wang, Gang Hu

Journal: Oncotarget. 2016 Mar;7(11):13122-38.

 

Autophagy is a tightly regulated process activated in response to metabolic stress and other microenvironmental changes. Astrocyte elevated gene 1 (AEG-1) reportedly induces protective autophagy. Our results indicate that AEG-1 also enhances the susceptibility of malignant glioma ...

Last Updated: 31 Dec 1969

Go To URL
Insight in glioma susceptibility through an analysis of 6p22.3, 12p13.33-12.1, 17q22-23.2 and 18q23 SNP genotypes in familial and non-familial glioma.
 

Author(s): Yanhong Liu, Beatrice S Melin, Preetha Rajaraman, Zhaoming Wang, Martha Linet, Sanjay Shete, Christopher I Amos, Ching C Lau, Michael E Scheurer, Spiridon Tsavachidis, Georgina N Armstrong, Richard S Houlston, Fay J Hosking, Elizabeth B Claus, Jill Barnholtz-Sloan, Rose Lai, Dora Il'yasova, Joellen Schildkraut, Siegal Sadetzki, Christoffer Johansen, Jonine L Bernstein, Sara H Olson, Robert B Jenkins, Daniel LaChance, Nicholas A Vick, Margaret Wrensch, Faith Davis, Bridget J McCarthy, Ulrika Andersson, Patricia A Thompson, Stephen Chanock, , Melissa L Bondy

Journal: Hum. Genet.. 2012 Sep;131(9):1507-17.

 

The risk of glioma has consistently been shown to be increased twofold in relatives of patients with primary brain tumors (PBT). A recent genome-wide linkage study of glioma families provided evidence for a disease locus on 17q12-21.32, with the possibility of four additional risk ...

Last Updated: 31 Dec 1969

Go To URL

Reviews from the PubMed Database

Review articles summarize what is currently known about a disease. They discuss research previously published by others.
The terms "Glioma susceptibility 1" returned 0 free, full-text review articles on human participants.

 
 
Top

Clinical Trial Information This information is provided by ClinicalTrials.gov

There are currently no open clinical trials for this condition.